A 69-year-old man attended our outpatient department with pain and discomfort just above both his knees. He said the problem had been troubling him for 4 months. On examination, we found swelling of the soft tissue at the end of the quadriceps tendon of his right leg (figure); the patient had a full range of movement of his knee with no weakness. The x-ray showed an ill-defined erosion of the…
Discontinuing adalimumab led to higher rates of recurrence of uveitis, arthritis, or both in patients with previously controlled juvenile idiopathic arthritis-associated uveitis. However, all patients…
The combination of glucocorticoids with immunosuppressive agents or intravenous immunoglobulin did not appear to reduce the risk of Susac syndrome relapse compared with glucocorticoids alone.…
New pathogenesis-based therapeutics and evidence-based consensus treatment recommendations, often with predefined treatment goals, have remarkably improved outcomes across many chronic diseases. However, a clinically significant…
Historical redlining could be a structural determinant of inequities in present-day health-care utilisation patterns. Policy interventions that dismantle structural racism could reduce inequities in access…
We read with interest the 2023 Hyperinflammation and HLH Across Speciality Collaboration consensus guideline1 in The Lancet Rheumatology and would like to highlight some areas…
Although the recently published treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica suggest minimising the use of glucocorticoids,1 these drugs are still the standard…
This study suggests that, compared with placebo, individuals with polymyalgia rheumatica receiving 4 mg baricitinib are less likely to need oral glucocorticoids to have low…
Rheumatoid arthritis-associated interstitial lung disease (ILD) is a severe extra-articular disease manifestation affecting 10% or more of patients with rheumatoid arthritis.1 Uncertainty about optimal immunosuppressive…
In US veterans with rheumatoid arthritis-associated ILD, no difference in outcomes were seen between those who started TNF inhibitors compared to those starting non-TNF biological…
Editors at The Lancet Rheumatology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A…
